The Adoption Gap Trap

Why Seed Stage MedTech Companies Stall After Their First Pilots

I keep seeing the same pattern.

A seed or small Series A MedTech company lands two or three solid pilots. The clinical feedback is positive. A couple of sites are using the product. The team feels momentum. They start talking about early traction and begin hiring or raising with that story.

Then the next six to nine months feel strangely flat. Pipeline conversations stretch. Value Analysis Committee discussions stall or request more data that doesn’t exist in usable form. The two happy sites stay happy but don’t turn into references that open doors elsewhere. Founder-led sales still carry almost every deal. Revenue stays lumpy or nonexistent.

This is the Adoption Gap in action.

Early pilot success proves that something can work under controlled conditions with engaged users. It does not prove that the solution will clear a Value Analysis Committee, integrate cleanly into existing workflows without constant hand-holding, generate measurable economic or operational outcomes that the hospital cares about, or create references who will actively advocate for you with peers. That distance between clinical proof and repeatable multi-stakeholder adoption is the gap most teams underestimate.

What pilot success actually buys you

A successful pilot is real progress. It is also incomplete progress. Most teams treat it as the main signal that product-market fit is arriving. In practice it is only the starting point for the commercial and operational work that has to come next.

You still need reusable evidence that speaks to the questions budget holders and VACs actually ask. You need a value story stable enough that someone other than the founder can deliver it. You need a small set of reference customers willing to speak about measurable results. You need clearer mapping of the full set of people who can slow or stop adoption inside a hospital. Without those pieces, every new opportunity starts from near zero.

When companies keep running more pilots instead of building these foundations, the pattern becomes familiar: more data requests, longer cycles, and little movement toward predictable revenue.

Where the stall usually shows up

I see the same weak spots surface again and again.

Evidence stays too clinical. Teams collect outcome data that impresses clinicians but does not address the economic or operational questions that determine whether a hospital will actually buy. Every new opportunity requires building evidence from scratch. There is no reusable package and no clear view of what will be needed over the next 12 to 18 months.

The core promise is still unstable. Messaging shifts depending on who is in the room. The team has not pressure-tested a clear value story with prospects outside the earliest relationships. Sales conversations stay founder-dependent and hard to hand off.

Referenceability is thin. Two or three sites may be using the product, but none are yet willing or positioned to speak credibly to outcomes with peers. Without those references, every new conversation starts from zero.

Workflow and multi-stakeholder understanding remain shallow. The solution works in the pilot setting, but the team has not proven it fits day-to-day workflows without heavy customization or support, and has not mapped the full set of stakeholders who can block progress.

These gaps are normal right after the first pilots. They become expensive when they persist.

Why this period matters so much

The companies that treat the post-pilot period as a deliberate bridge do something different. They use the early sites to generate the specific evidence and references that later buyers will demand. They harden the value story. They start building a small network of clinical champions who can open doors. They get clearer on the documentation and outcomes VACs will require. They stop treating every new opportunity as a custom science project.

None of this is glamorous. It is the work that determines whether early clinical validation turns into something durable.

Teams that skip it often look busy. More pilots, more conference presentations, more “interesting” conversations. The underlying conversion mechanics stay weak.

A practical way to pressure-test where you stand

If you are in this window, a few diagnostic questions are useful:

1. Can you point to a simple evidence roadmap that covers the clinical, operational, and economic outcomes needed for the next set of VAC discussions?
2. Do you have at least two or three reference customers who are actively willing to speak about measurable results?
3. Is the core value message stable enough that someone other than the founder can deliver it consistently?
4. When a new opportunity appears, how much of the supporting material already exists versus how much has to be built from scratch?
5. Are you seeing real movement toward decisions and implementation, or mostly polite interest that never converts?

Honest answers to those questions usually reveal whether the company is still inside the Adoption Gap or starting to cross it.

Closing the gap is a choice

The Adoption Gap trap is common because pilot success feels like progress. It is progress. It is just not the kind that automatically produces repeatable adoption. The teams that avoid long stalls treat the period after the first pilots as the time to build the commercial and evidence infrastructure that later growth will require. They do not wait for the next pilot or the next funding conversation to force the issue.

If you are running a seed or small Series A MedTech company and the early clinical signals look good but the commercial path still feels unclear, this is the moment to diagnose the gap rather than simply run more pilots.

The free 7-Lever Self-Assessment is designed for exactly this stage of the journey. It walks through the specific foundations that matter after early clinical validation and gives a clear readout of where the biggest gaps sit. You can get it through the form on the homepage. If you want to walk through the results or pressure-test the next 6–12 months of work, I’m happy to do a focused strategy conversation; just hit the Book a Call button at the top of the page.